Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension

References

• HeijlALeskeMCBengtssonBHymanLBengtssonBHusseinMEarly Manifest Glaucoma Trial GroupReduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma TrialArch Ophthalmol2002120101268127912365904
   PubMed Web of Science ®Google Scholar
• The Advanced Glaucoma Intervention Study (AGIS): 7The relationship between control of intraocular pressure and visual field deterioration. The AGIS InvestigatorsAm J Ophthalmol2000130442944011024415
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol2002120670171312049574
   PubMed Web of Science ®Google Scholar
• The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucomaCollaborative Normal-Tension Glaucoma Study GroupAm J Ophthalmol199812644985059780094
   PubMed Web of Science ®Google Scholar
• European Glaucoma SocietyTerminology and Guidelines for Glaucoma3rd edSavonaDogma2008
   Google Scholar
• BeanGWCamrasCBCommercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differencesSurv Ophthalmol200853 Suppl 1S69S8419038626
   PubMed Web of Science ®Google Scholar
• NakajimaTMatsugiTGotoWNew fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agentsBiol Pharm Bull200326121691169514646172
   PubMed Web of Science ®Google Scholar
• TakagiYNakajimaTShimazakiAPharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drugExp Eye Res200478476777615037111
   PubMed Web of Science ®Google Scholar
• SuttonAGouwsPRopoATafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteersInt J Clin Pharmacol Ther200846840040618793581
   PubMed Web of Science ®Google Scholar
• UusitaloHPillunatLERopoAPhase III Study InvestigatorsEfficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III studyActa Ophthalmol2010881121920420586
   PubMed Web of Science ®Google Scholar
• TraversoCERopoAPapadiaMUusitaloHA phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprostJ Ocul Pharmacol Ther20102619710420148656
   PubMed Web of Science ®Google Scholar
• KuwayamaYKomemushiSTafluprost Multi-center Study GroupIntraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III studyNihon Ganka Gakkai Zasshi20101145436443 Japanese20545217
   PubMedGoogle Scholar
• ChabiAVarmaRTsaiJCRandomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertensionAm J Ophthalmol201215361187119622310086
   PubMed Web of Science ®Google Scholar
• BaudouinCSide effects of antiglaucomatous drugs on the ocular surfaceCurr Opin Ophthalmol199672808610163327
   PubMedGoogle Scholar
• VaedeDBaudouinCWarnetJMBrignole-BaudouinFPreservatives in eye drops: toward awareness of their toxicityJ Fr Ophthalmol2010337505524 French
   Web of Science ®Google Scholar
• BrasnuEBrignole-BaudouinFRianchoLGuenounJMWarnetJMBaudouinCIn vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell lineCurr Eye Res200833430331218398704
   PubMed Web of Science ®Google Scholar
• LiangHBaudouinCPaulyABrignole-BaudouinFConjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chlorideBr J Ophthalmol20089291275128218723745
   PubMed Web of Science ®Google Scholar
• KahookMYNoeckerRQuantitative analysis of conjunctival goblet cells after chronic application of topical dropsAdv Ther200825874375118670744
   PubMed Web of Science ®Google Scholar
• JaenenNBaudouinCPouliquenPManniGFigueiredoAZeyenTOcular symptoms and signs with preserved and preservative-free glaucoma medicationsEur J Ophthalmol200717334134917534814
   PubMed Web of Science ®Google Scholar
• PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBr J Ophthalmol200286441842311914211
   PubMed Web of Science ®Google Scholar
• NordmannJPAuzanneauNRicardSBerdeauxGVision related quality of life and topical glaucoma treatment side effectsHealth Qual Life Outcomes200317514667241
   PubMedGoogle Scholar
• ZimmermanTJHahnSRGelbLTanHKimEEThe impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistenceJ Ocul Pharmacol Ther200925214515219284321
   PubMed Web of Science ®Google Scholar
• AriasASchargelKUssaFCanutMIRoblesAYSánchezBMPatient persistence with first-line antiglaucomatous monotherapyClin Ophthalmol2010426126720463793
   PubMedGoogle Scholar
• LeungEWMedeirosFAWeinrebRNPrevalence of ocular surface disease in glaucoma patientsJ Glaucoma200817535035518703943
   PubMed Web of Science ®Google Scholar
• ErbCGastUSchremmerDGerman register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eyeGraefes Arch Clin Exp Ophthalmol2008246111593160118648841
   PubMed Web of Science ®Google Scholar
• BaudouinCRenardJPNordmannJPPrevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertensionEur J Ophthalmol Epub June 11, 2012
   Web of Science ®Google Scholar
• LawinMJWormaldRPMigdalCSHitchingsRAThe influence of prior therapy on the success of trabeculectomyArch Ophthalmol199010811154315482244836
   PubMedGoogle Scholar
• Santen Oy Taflotan^® [summary of product characteristics]TampereSanten Oy2008
   Google Scholar
• MizoguchiTOzakiMUnokiKDakeYEtoTAraiMA randomized crossover study comparing tafluprost 0.0015% with travoprost 0.004% in patients with normal-tension glaucoma [corrected]Clin Ophthalmol201261579158423055682
   PubMedGoogle Scholar
• AngAReddyMAShepstoneLBroadwayDCLong term effect of latanoprost on intraocular pressure in normal tension glaucomaBr J Ophthalmol200488563063415090413
   PubMed Web of Science ®Google Scholar
• AngGSKerseyJPShepstoneLBroadwayDCThe effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised controlled trialBr J Ophthalmol20089281129113318511540
   PubMed Web of Science ®Google Scholar
• SuhMHParkKHKimDMEffect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucomaJpn J Ophthalmol2009531182319184304
   PubMed Web of Science ®Google Scholar
• TsumuraTYoshikawaKSuzumuraHBimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse eventsClin Ophthalmol201261547155223055677
   PubMedGoogle Scholar
• DirksMSNoeckerRJEarlMRohSSilversteinSMWilliamsRDA 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucomaAdv Ther200623338539416912020
   PubMed Web of Science ®Google Scholar
• SawadaAYamamotoTTakatsukaNRandomized crossover study of latanoprost and travoprost in eyes with open-angle glaucomaGraefes Arch Clin Exp Ophthalmol2012250112312921858678
   PubMed Web of Science ®Google Scholar
• NomuraYNakakuraSMoriwakiMTakahashiYShirakiKEffect of travoprost on 24-hour intraocular pressure in normal tension glaucomaClin Ophthalmol2010464364720689776
   PubMedGoogle Scholar
• KonstasAGKozobolisVPKatsimprisIEEfficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patientsOphthalmology2007114465365717197028
   PubMed Web of Science ®Google Scholar
• KonstasAGHollóGIrkecMDiurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observermasked, three-centre studyBr J Ophthalmol200791675776017124241
   PubMed Web of Science ®Google Scholar
• JohnsonTVFanSCamrasCBTorisCBAqueous humor dynamics in exfoliation syndromeArch Ophthalmol2008126791492018625936
   PubMedGoogle Scholar
• HedmanKAlmAA pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timololEur J Ophthalmol20001029510410887918
   PubMed Web of Science ®Google Scholar
• DenisPBaudouinCBronAFirst-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressureBMC Ophthalmol201010420181282
   PubMed Web of Science ®Google Scholar
• HommerAMohammed RamezOBurchertMKimmichFIOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucomaCurr Med Res Opin20102681905191320553122
   PubMed Web of Science ®Google Scholar
• UusitaloHMPillunatLEBaudouinCPhase III, 24-month study investigating the efficacy and safety of tafluprost vs latanoprost in patients with open-angle glaucoma or ocular hypertensionActa Ophthalmol200886SupplS243
   Google Scholar
• HamacherTAiraksinenJSaarelaVLiinamaaMJRichterURopoAEfficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysisActa Opthtalmol Suppl (Oxf)2008S2421419
   Google Scholar
• UusitaloHChenEPfeifferNSwitching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medicationActa Ophthalmol201088332933620546237
   PubMed Web of Science ®Google Scholar
• JanulevičienėIDerkačIGrybauskieneLPaulauskaitėRGromnickaiteRKuzmienėLEffects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucomaClin Ophthalmol2012610310922275814
   PubMedGoogle Scholar
• FaridiUASalehTAEwingsPComparative study of three prostaglandin analogues in the treatment of newly diagnosed cases of ocular hypertension, open-angle and normal tension glaucomaClin Experiment Ophthalmol201038767868220456437
   PubMed Web of Science ®Google Scholar